MedTrace Logo

Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database

NCT06600009 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 534

Last updated 2024-09-19

No results posted yet for this study

Summary

This study was a retrospective non-interventional cohort study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The study setting was defined as follows:

* The inclusion period covered 01 February 2015 to 30 September 2020.
* The study period covered 01 August 2014 to 30 September 2021 inclusive.
* The index date was defined as the date of the first prescription of secukinumab or adalimumab within the inclusion period.
* The pre-index period was defined as the 6-month period before the index date (exclusive).
* Patients were followed until death, discontinuation of treatments of interest or end of the study period, whichever occurred first.

Conditions

Interventions

DRUG

Secukinumab

Patients had received secukinumab per their dosing regimens prior to this observational study.

DRUG

Adalimumab

Patients had received adalimumab per their dosing regimens prior to this observational study.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2023-08-21
Completion
2023-09-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600009 on ClinicalTrials.gov